Bortezomib in Treating Patients With Lymphoproliferative Disorders

Inclusion Criteria: * Histologically or cytologically confirmed lymphoproliferative disorder of 1 of the following subtypes: * \* Relapsed or refractory grade I, II, or III follicular center cell lymphoma * Relapsed or refractory mantle cell lymphoma * Measurable disease for non-Hodgkin's lymphoma (NHL) only * At least 1 unidimensionally measurable lesion * At least 2 cm by conventional techniques OR at least 1 cm by spiral CT scan * Lymph nodes no greater than 1 cm in short axis considered normal * Absolute lymphocytosis greater than 5,000/mm\^3 with B-cell phenotype (CD19, 20,or 23 positive) with more than 30% bone marrow lymphocytes for CLL or other leukemic forms of NHL * No known brain metastases * Performance status - Karnofsky 70-100% * At least 3 months * See Disease Characteristics * Absolute neutrophil count greater than 1,500/mm\^3 (500/mm\^3 if lymphomatous involvement of bone marrow) * Platelet count greater than 50,000/mm\^3 * Bilirubin less than 1.5 times upper limit of normal (ULN) * AST and ALT no greater than 2.5 times ULN (4 times ULN in case of liver metastases) * Creatinine less than 1.5 times ULN * No symptomatic congestive heart failure * No New York Heart Association class III or IV heart disease * No unstable angina pectoris * No cardiac arrhythmia * No myocardial infarction within the past 6 months * No cerebrovascular accident or transient ischemic attack within the past 6 months * No history of orthostatic hypotension * No evidence of acute ischemia or significant conduction abnormality (left anterior hemiblock in the presence of right bundle branch block or second or third degree atrioventricular blocks) on electrocardiogram * No uncontrolled hypertension requiring antihypertensive medication * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Febrile episodes up to 38.5°C allowed if no evidence of active infection * No other uncontrolled concurrent illness * No known or active HIV infection * No ongoing or active infection * No psychiatric illness or social situation that would preclude study entry * At least 3 months since prior monoclonal antibody therapy (e.g., rituximab) * No more than 3 prior regimens of conventional cytotoxic chemotherapy * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * At least 1 week since prior steroid therapy * At least 4 weeks since prior radiotherapy and recovered * At least 4 weeks since prior major surgery * No other concurrent investigational agents